Licit Substance Use and Premenstrual Syndrome Symptom Severity in Female College Students
- PMID: 35651989
- PMCID: PMC9148642
- DOI: 10.1089/whr.2021.0117
Licit Substance Use and Premenstrual Syndrome Symptom Severity in Female College Students
Abstract
Introduction: Premenstrual syndrome (PMS) affects the majority of women and is characterized by physical, behavioral, and mood symptoms, which can have a profound impact on quality of life. PMS symptoms have also been linked to licit substance use. This study examined the relationships between daily/problem use (DPU) of caffeine (Caf+), alcohol (Alc+), and tobacco (Cig+) and PMS symptomology in a sample of college women.
Methods: Participants (N = 196) completed an anonymous one-time health survey. Demographic, PMS symptomatology, and DPU of licit substance variables were examined. Independent t-tests compared PMS symptom scores in women with and without Caf+, Cig+, and Alc+ use. One-way analysis of variances examined the associations between PMS symptom severity and number of DPU-positive substances.
Results: PMS subscale severity (pain [F(2,190) = 4.47, p = 0.013], affective [F(2,192) = 8.21, p < 0.001], and water retention [F(2,191) = 13.37, p < 0.001]) and total PMS symptom severity [F(2,189) = 10.22, p < 0.001] showed a dose response effect, with the number of licit substances with DPU significantly associated with PMS symptom severity.
Conclusions: This study findings provide important new information about the relationship between PMS symptoms and at-risk substance use. These are cross-sectional data, however, and affirm a need for longitudinal research to better understand the associations, with a focus on potential benefits of education and intervention.
Keywords: alcohol; caffeine; college students; premenstrual syndrome; tobacco.
© Kathryn Polak et al., 2022; Published by Mary Ann Liebert, Inc.
Conflict of interest statement
No competing financial interests exist.
Figures
References
-
- Dennerstein L, Lehert P, Heinemann K. Epidemiology of premenstrual symptoms and disorders. Menopause Int 2012;18:48–51. - PubMed
-
- Freeman EW. Premenstrual syndrome and premenstrual dysphoric disorder: Definitions and diagnosis. Psychoneuroendocrinology 2003;28 Suppl 3:25–37. - PubMed
-
- Rapkin AJ, Winer SA. Premenstrual syndrome and premenstrual dysphoric disorder: Quality of life and burden of illness. Expert Rev Pharmacoecon Outcomes Res 2009;9:157–170. - PubMed
-
- Sveindóttir H, Bäckström T. Prevalence of menstrual cycle symptom cyclicity and premenstrualdysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 2000;79:405–413. - PubMed
-
- Wittchen H-U, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119–132. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous